Abelcet (ABLC) in the treatment of severe invasive fungal infections.

Abstract

Review of Abelcet indications based on clinical trials in the most common opportunistic micromycetes infections (candidiasis, aspergillosis, mukormycosis, cryptococcosis) in the context of other antifungal agents.

Keywords

• Abelcet
• candidiasis
• aspergillosis
• mukormycosis
• cryptococcosis
• antifungal agents
• micromycetes infections